Sera Prognostics (NASDAQ:SERA – Get Free Report) and BrightSpring Health Services (NASDAQ:BTSG – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Volatility and Risk
Sera Prognostics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, BrightSpring Health Services has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.
Insider & Institutional Ownership
54.6% of Sera Prognostics shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by insiders. Comparatively, 3.4% of BrightSpring Health Services shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,535.05 | -$32.90 million | ($0.85) | -3.84 |
| BrightSpring Health Services | $11.27 billion | 0.45 | -$18.06 million | $0.31 | 93.13 |
BrightSpring Health Services has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Sera Prognostics and BrightSpring Health Services, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 0 | 0 | 1.00 |
| BrightSpring Health Services | 0 | 2 | 9 | 0 | 2.82 |
BrightSpring Health Services has a consensus target price of $29.13, indicating a potential upside of 0.88%. Given BrightSpring Health Services’ stronger consensus rating and higher possible upside, analysts clearly believe BrightSpring Health Services is more favorable than Sera Prognostics.
Profitability
This table compares Sera Prognostics and BrightSpring Health Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -30,306.48% | -45.86% | -34.31% |
| BrightSpring Health Services | 0.55% | 9.29% | 2.64% |
Summary
BrightSpring Health Services beats Sera Prognostics on 11 of the 14 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About BrightSpring Health Services
BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
